22nd Century Announces Important New Achievements with KeyGene
March 11, 2020 16:15 ET
|
22nd Century Group, Inc.
Delivers Complete High-Quality Hemp/Cannabis Genome Sequence; Establishes New Proprietary Hemp/Cannabis Bioinformatics Platform WILLIAMSVILLE, N.Y. , March 11, 2020 (GLOBE NEWSWIRE) -- 22nd Century...
CORRECTION: Further Support for Reducing Nicotine in Cigarettes to Non-Addictive Levels: New Studies Confirm Use of Very Low Nicotine Content Cigarettes Does Not Lead to Compensatory Smoking
March 04, 2020 13:03 ET
|
22nd Century Group, Inc.
Williamsville, NY, March 04, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE AMERICAN: XXII), a plant biotechnology company that is a leader in reduced nicotine tobacco and hemp/cannabis...
22nd Century Group to Present its Modified Risk Tobacco Product Application to FDA’s Tobacco Products Scientific Advisory Committee
December 23, 2019 15:39 ET
|
22nd Century Group, Inc.
Williamsville, NY, Dec. 23, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine...